Biote Stock Price, News & Analysis

Biote (NASDAQ:BTMD), a provider of personalized hormone optimization and therapeutic wellness solutions, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, after market close.

The company will host a conference call at 5:00 p.m. ET the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A webcast replay will be available on Biote's Investor Relations website after the event.

Biote Corp (NASDAQ: BTMD), a provider of personalized hormone optimization and therapeutic wellness solutions, has appointed Rich Barrera to its Board of Directors. Barrera, who is the Founder and CEO of Roystone Capital, brings over 20 years of investment management experience to the role. His firm Roystone Capital is one of Biote's major institutional shareholders. Prior to founding Roystone in 2012, Barrera held positions at Redwood Capital Management and Glenview Capital Management. He previously served as Chair of the Finance Committee at Pacific Gas & Electric and holds an MBA from Harvard Business School and a BS in Accounting and Finance from the Wharton School.

Biote (BTMD) reported strong Q1 2025 financial results with revenue of $49.0 million, up 4.7% year-over-year. The company achieved a net income of $15.8 million and diluted EPS of $0.37, compared to a net loss in the previous year. Gross profit margin improved to 74.3%, primarily due to vertical integration of their 503B manufacturing facility. While dietary supplements revenue increased 25.5%, procedure revenue decreased 3.6%. The company announced a strategic restructuring to enhance sales force productivity, including a 25% increase in sales representatives through internal reorganization. Biote maintained its 2025 guidance with expected revenue of $202-208 million and Adjusted EBITDA of $59-64 million. The restructuring will incur charges of $0.6-0.8 million in Q2 2025.

Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has announced its upcoming first quarter 2025 financial results release. The company will present its results on Wednesday, May 7, 2025, after market close, followed by a conference call at 5:00 p.m. ET.

Investors can access the conference call via U.S. toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website Events page after the call concludes.

Biote Corp (NASDAQ: BTMD) announced significant insider stock purchases, with several Board of Directors members and CEO Bret Christensen collectively acquiring approximately 260,000 shares through open market transactions.

Executive Chairman Marc Beer expressed confidence in the company's business strategy and long-term outlook, specifically highlighting CEO Christensen's capabilities to implement decisive changes for business growth. Beer emphasized Christensen's extensive background in diagnostic, therapeutic, and medical device healthcare sectors as key qualifications for leading Biote's expansion.

Biote (NASDAQ: BTMD) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue increased 6.4% to $197.2 million, with procedure revenue reaching $150.3 million. The company achieved a gross profit margin of 70.5% and net income of $0.05 million.

In Q4 2024, revenue grew 9.0% to $49.8 million, with procedure revenue up 5.0%. However, Q4 net income decreased to $3.5 million ($0.10 per share) from $12.1 million ($0.18 per share) in Q4 2023. The quarter saw a 71.8% gross profit margin and Adjusted EBITDA of $15.1 million.

For fiscal 2025, Biote projects procedure revenue growth of 2-4% and dietary supplements revenue increase of 5-10%. The company plans to focus on maximizing top-tier providers, expanding practitioner network, and strengthening commercial execution.

Biote (Nasdaq: BTMD), a provider of preventive health care solutions specializing in personalized hormone optimization and therapeutic wellness, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close.

The company will host a conference call at 5:00 p.m. ET on the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast will be available, and a replay will be posted on the Events page of Biote's Investor Relations website following the call.

AccessHope announces expansion of its executive leadership team with key appointments amid rapid growth. Dr. Yousuf Zafar, a Duke University oncologist and former Optum executive, joins as Chief Medical Officer. Peter Bridges, a veteran digital health leader, becomes Chief Strategy and Growth Officer, while Debra Morris is promoted to President.

The company, which delivers leading-edge cancer expertise, recently completed a spinout from City of Hope and secured $33 million in Series B funding. AccessHope has experienced double-digit annual growth since its founding and expanded its network of partnerships with NCI-Designated Comprehensive Cancer Centers, including prestigious institutions like Dana-Farber Cancer Institute and Johns Hopkins Medicine.

Biote (NASDAQ: BTMD) announced its Q3 2024 financial results. Revenue stood at $51.4 million, a 12.8% increase from the prior year. Procedure revenue was $37.9 million. Gross profit margin improved to 70.5%, driven by vertical integration and cost management. Net income was $12.7 million, with diluted EPS at $0.33, compared to $19.6 million and $0.24 respectively, in Q3 2023. Adjusted EBITDA grew to $16.2 million, with a margin of 31.5%.

Despite temporary disruptions from enhanced clinical decision support software and hurricane-related clinic closures, Biote anticipates procedure revenue growth to reaccelerate in 2025. The company launched proprietary software to bolster its competitive edge. Due to these disruptions, Biote adjusted its 2024 financial guidance to $197-$201 million in revenue and $58-$61 million in Adjusted EBITDA, down from $200-$204 million and $60-$63 million respectively.